EUCTR2005-000121-30-IT进行中（未招募）不适用
An Open Label Pilot study with oral fludarabine, oral cyclophosphamide and CAMPATH 1H (FCC) for patients with refractory or Relapsed B cells Chronic Lynphocytic Leukaemia - FCC
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2007年11月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •signed informed consent
- •male or female > 17 years
- •WHO performance status 0-II
- •life expectancy at least 6 months
- •confirmation of LLC-B
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •No previous chemotherapy or immunotherapy
- •Previous CAMPATH 1H admistered in combination with chemotherapy
- •HIV HBV HCV positive
研究者
相似试验
进行中（未招募）
不适用
A phase II study in patients with fludarabine refractory CLL: Dasatinib treatment combination for Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) - D’accord studyEUCTR2008-002236-15-NLAcademic Medical Center
尚未招募
2 期
A Clinical Study to check the Oral Safety and Efficacy of toothpaste in Healthy Adult SubjectsCTRI/2022/06/043011Himalaya wellness company
尚未招募
2 期
A Clinical Study to check the Oral Safety & Efficacy of Himalaya Botanique Complete care toothpaste in Healthy Adult SubjectsCTRI/2022/07/043756Himalaya wellness company
尚未招募
2 期
A clinical study to check the safety and effectiveness of toothpasteCTRI/2022/08/044960Himalaya wellness company
尚未招募
3 期
Safety & Efficacy of HDNT-072012CTRI/2022/02/040379Himalaya Wellness Company